Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of$ 0.53. This compares to loss of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 5.66%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.42 per share when it actually produced a loss of $0.37, delivering a surprise of 11.90%.Over the last four quarters, t ...